Key result
Laboratory testing, including platelet function tests and CYP2C19 genotyping, is summarized for evaluating clopidogrel responsiveness and addressing FDA warnings on genetic polymorphisms.
Provides an overview of laboratory and genetic testing methods to evaluate clopidogrel responsiveness in the context of FDA warnings regarding CYP2C19 polymorphisms.
Answers are grounded in this paper and cite their sources.
Laboratory testing summaries address FDA clopidogrel warnings; leaves open whether routine genotyping improves outcomes.
Clopidogrel is a widely used antiplatelet agent that irreversibly inhibits platelet P2Y12 ADP receptors after conversion to an active metabolite. There are a number of laboratory tests capable of detecting clopidogrel-induced platelet inhibition and published literature correlates suboptimal clopidogrel response to adverse cardiovascular outcomes. Genetic polymorphisms are thought to affect conversion of the prodrug to the active metabolite, and the FDA has recently added a black-box warning to clopidogrel to highlight the effects of these polymorphisms on drug bioavailability and to inform prescribers about the availability of genetic testing. For these reasons, there is growing interest in the use of laboratory tests to monitor patients treated with clopidogrel. This article summarizes the currently available laboratory testing, including platelet function tests and genotyping for CYP2C19 variants.
No takes yet. Share an insight, caveat, or question.
Smock et al. (2011) conducted a review in Clopidogrel responsiveness. Laboratory testing (platelet function tests and CYP2C19 genotyping) was evaluated. Laboratory testing, including platelet function tests and CYP2C19 genotyping, is summarized for evaluating clopidogrel responsiveness and addressing FDA warnings on genetic polymorphisms.
Synapse has enriched 10 related papers. Consider them for comparative context: